drugset

drugset / Trial / NCT00134953

Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

NCT00134953 ↗

Phase 3 Terminated 24 enrolled Novartis

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).

Timeline

Start: 2003-01
Primary completion: —
Completion: 2004-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivastigmine	Small molecule	—	—

Indications